Oncology Clinical Trial Finder
Breast Cancer

Completed • Phase I • Stage I, II, III • Post-Menopausal • Interventional

The following is imported from ClinicalTrials.gov:

68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer

This trial studies how well 68-Ga RM2 works with PET/MRI in imaging patients with estrogen receptor-positive breast cancer. 68-Ga-RM2 is an agent used in diagnostic imaging.

PRIMARY OBJECTIVES: I. To evaluate the feasibility of 68-Ga RM2 PET/MRI for identification of estrogen receptor positive primary breast cancer and metastases OUTLINE: Patients receive 68-Ga-RM2 intravenously (IV) and after 45 minutes undergo PET/MRI over 30-60 minutes. After completion of study, patients are followed up at 24-72 hours, and then for 12 months.

Breast Cancer

Study Design
Study type:


Estimated enrollment:

5 participant

Actual study start date:

March 19, 2019

Eligibility Criteria
Ages eligible for study:

18 - 999

Sexes eligible for study:


Arms and Intervention
  • Gallium Ga 68-labeled GRPR Antagonist BAY86-7548

  • Magnetic Resonance Imaging

  • Positron Emission Tomography

  • Investigational software and coils in PET/MR scan

Inclusion criteria
  • er+ breast cancer at initial diagnosis prior to surgery or at recurrence (at least one er+ lesion based on results of biopsy).

  • able to provide written consent

  • karnofsky performance status of ≥ 50 (or eastern cooperative oncology group (ecog)/world health organization (who) equivalent)

Exclusion criteria
  • less than 18 years-old at the time of radiotracer administration

  • inability to lie still for the entire imaging time

  • inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)

  • any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the investigator, may significantly interfere with study compliance

  • renal function impairment preventing administration of mri contrast

  • metallic implants (contraindicated for mri)

Trial Information at Site
Last Updated:
Trial Information
ClinicalTrial.gov ID:


Estimated Enrollment:


Last Updated:


Principal Investigator

Andrei Iagaru

Trial Sponsor

Andrei Iagaru

Study Location (1)

Stanford Cancer Institute Palo Alto

Palo Alto, California, United States


© 2024 Outcomes4Me Inc. All rights reserved.